

**Review Form 1.6**

Journal Name:	<a href="#">International Blood Research &amp; Reviews</a>
Manuscript Number:	Ms_IBRR_90006
Title of the Manuscript:	IS DEFIBROTIDE PROPHYLAXIS EFFECTIVE ON GRAFT VERSUS HOST DISEASE IN PATIENTS WITH ALLOGENEIC STEM CELL TRANSPLANTATION?
Type of the Article	Original Research Article

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journalibrr.com/index.php/IBRR/editorial-policy> )

**PART 1: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments		
<b>Minor</b> REVISION comments		
<b>Optional/General</b> comments	<p>Defibrotide (DF) is used effectively in SOS prophylaxis and treatment. Graft versus host disease (GVHD) is a significant cause of morbidity and mortality in allo-SCT. In this study investigation done on the effect of DF on the development of GVHD in patients. 81 allo-transplanted patients evaluated due to various diagnoses (benign or malignant), retrospectively. Thirty-four patients used DF as prophylaxis while 47 patients did not receive it. Acute and chronic GVHD assessments were performed at +30/100<sup>th</sup> day and throughout the life of the patients, respectively. Acute GVHD was more common with DF use (82% vs 61%). There was no statistical significance in terms of the effect on chronic GVHD. Results shows that one patient in the non-DF group developed SOS. DF may be beneficial to prevent acute GVHD. However, it is observed that GVHD and mortality were more common in patients using DF. This is probably due to the similarity of high-risk criteria between GVHD and SOS. In this study researcher not found a significant association between defibrotide use and the development of chronic GVHD.</p> <p><b>Script is very well written. Recommended for publication in the Journal.</b></p>	

**PART 2:**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

[Review Form 1.6](#)

**Reviewer Details:**

Name:	<b>Amit Gupta</b>
Department, University & Country	<b>Dr. B R Ambedkar University, India</b>